← Zhe Jiang Li Zi Yuan Food overview

Zhe Jiang Li Zi Yuan Food vs CSPC Innovation Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhe Jiang Li Zi Yuan Food Co Ltd (605337.CG)

Q3 2026
▲2▼2

Liziyuan profit slumps, director probed, but dairy cycle turns up

  • Raw milk cycle turning up lifts dairy stocks Milk prices are rising and the national dairy herd keeps shrinking, so investors bet the long dairy downturn is ending. Liziyuan shares jumped to their daily limit in a sector-wide rally. If milk prices keep recovering, demand and pricing for dairy drinks should improve, helping the stock.

    This is the main positive force behind the stock's move and explains the sector rally it joined.

  • First-half profit down 32% on weak sales and costs Liziyuan's first-half net profit fell 32.3% to 65 million yuan, revenue slipped 2.7%, and second-quarter profit dropped 61.5%. The company blamed lower sales of milk-containing drinks and higher raw material costs. Weak earnings weigh on the stock because the business is still shrinking.

    This is the company's own hard result and the clearest negative driver for the share price.

  • Big dividend payout cushions weak results Alongside the weak report, Liziyuan plans to pay 1.3 yuan per 10 shares, about 49.8 million yuan, or 76.6% of its profit. Paying out most earnings signals confidence and gives shareholders cash, which supports the stock and softens the blow of falling profit.

    It is a concrete shareholder-return action that offsets the negative earnings news.

  • Independent director under investigation for serious violations Director Xiao Zuoping, who chairs Liziyuan's audit committee, is being investigated for suspected serious disciplinary and legal violations. He also sits on two other listed boards. The company says the case is unrelated to it and won't hurt operations, but an audit-committee head under probe raises governance worries.

    It is the newest event and a governance risk that can pressure the stock despite company reassurances.

September 2026
▲2▼2

Liziyuan profit slumps, director probed, but dairy cycle turns up

  • Raw milk cycle turning up lifts dairy stocks Milk prices are rising and the national dairy herd keeps shrinking, so investors bet the long dairy downturn is ending. Liziyuan shares jumped to their daily limit in a sector-wide rally. If milk prices keep recovering, demand and pricing for dairy drinks should improve, helping the stock.

    This is the main positive force behind the stock's move and explains the sector rally it joined.

  • First-half profit down 32% on weak sales and costs Liziyuan's first-half net profit fell 32.3% to 65 million yuan, revenue slipped 2.7%, and second-quarter profit dropped 61.5%. The company blamed lower sales of milk-containing drinks and higher raw material costs. Weak earnings weigh on the stock because the business is still shrinking.

    This is the company's own hard result and the clearest negative driver for the share price.

  • Big dividend payout cushions weak results Alongside the weak report, Liziyuan plans to pay 1.3 yuan per 10 shares, about 49.8 million yuan, or 76.6% of its profit. Paying out most earnings signals confidence and gives shareholders cash, which supports the stock and softens the blow of falling profit.

    It is a concrete shareholder-return action that offsets the negative earnings news.

  • Independent director under investigation for serious violations Director Xiao Zuoping, who chairs Liziyuan's audit committee, is being investigated for suspected serious disciplinary and legal violations. He also sits on two other listed boards. The company says the case is unrelated to it and won't hurt operations, but an audit-committee head under probe raises governance worries.

    It is the newest event and a governance risk that can pressure the stock despite company reassurances.

Latest
▲2▼2

Liziyuan profit slumps, director probed, but dairy cycle turns up

  • Raw milk cycle turning up lifts dairy stocks Milk prices are rising and the national dairy herd keeps shrinking, so investors bet the long dairy downturn is ending. Liziyuan shares jumped to their daily limit in a sector-wide rally. If milk prices keep recovering, demand and pricing for dairy drinks should improve, helping the stock.

    This is the main positive force behind the stock's move and explains the sector rally it joined.

  • First-half profit down 32% on weak sales and costs Liziyuan's first-half net profit fell 32.3% to 65 million yuan, revenue slipped 2.7%, and second-quarter profit dropped 61.5%. The company blamed lower sales of milk-containing drinks and higher raw material costs. Weak earnings weigh on the stock because the business is still shrinking.

    This is the company's own hard result and the clearest negative driver for the share price.

  • Big dividend payout cushions weak results Alongside the weak report, Liziyuan plans to pay 1.3 yuan per 10 shares, about 49.8 million yuan, or 76.6% of its profit. Paying out most earnings signals confidence and gives shareholders cash, which supports the stock and softens the blow of falling profit.

    It is a concrete shareholder-return action that offsets the negative earnings news.

  • Independent director under investigation for serious violations Director Xiao Zuoping, who chairs Liziyuan's audit committee, is being investigated for suspected serious disciplinary and legal violations. He also sits on two other listed boards. The company says the case is unrelated to it and won't hurt operations, but an audit-committee head under probe raises governance worries.

    It is the newest event and a governance risk that can pressure the stock despite company reassurances.

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 2026
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 2026
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.